Table 2A. Univariate analysis of prognosis TUBB3 immunohistochemistry.
| Factor TUBB3 | n | 5 y SR | Hazard-ratio | Median survival | Signif. |
|---|---|---|---|---|---|
| (95% CI) | (95% CI) | ||||
| All patients | 280 | 35% | 2.15 (1.9-14.0) y | p=0.0003 | |
| negative | 65 | 49% | Reference | 3.82 (2.0-14.0) y | |
| weak/moderate | 151 | 36% | 1.27 (0.9-1.8) | 2.21 (1.9-3.6) y | |
| strong | 64 | 16% | 2.21 (1.4-3.5) | 1.27 (1.0-1.9) y | |
| Primary surgery | 98 | 46% | 3.76 (1.9-10.1) y | p=0.0071 | |
| negative | 28 | 65% | Reference | 13.21 (3.8-14.0) y | |
| weak/moderate | 58 | 43% | 1.94 (1.1-3.6) | 3.10 (1.6-10.0) y | |
| strong | 12 | 17% | 3.60 (1.4-9.3) | 1.24 (1.0-2.8) y | |
| neoadjuvant | 182 | 27% | 1.92 (1.5-2.2) y | p=0.0130 | |
| negative | 37 | 36% | Reference | 2.04 (1.8-6.5) y | |
| weak/moderate | 93 | 32% | 1.02 (0.7-1.6) | 2.16 (1.9-2.8) y | |
| strong | 52 | 13% | 1.74 (1.0-2.9) | 1.10 (0.9-1.7) y | |
| neoadjuvant | |||||
| minor response | 160 | 23% | 1.85 (1.4-2.2) y | p=0.0050 | |
| negative | 30 | 33% | Reference | 2.04 (0.8-6.5) y | |
| weak/moderate | 85 | 28% | 1.01 (0.6-1.6) | 2.12 (1.8-2.5) y | |
| strong | 45 | 9% | 1.87 (1.1-3.3) | 1.10 (0.7-1.5) y |